Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran

World Journal of Gastroenterology

Volumn 12, Issue 26, 2006, Pages 4203-4205

  Alizadeh, Amir Houshang Mohammad ^a   Ranjbar, Mitra ^b   Karimi, Babak ^b   Hatami, Saeed ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis B; HBeAg; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IRAN; MALE; MEDICAL RECORD REVIEW; MYALGIA; NONHUMAN; RELAPSE; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 33748591069     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i26.4203     Document Type: Article

References (18)

1. Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and in Iran: epidemiology, diagnosis, and follow up. Scien J Med Council 1997; 15: 183-200
2. Gagnon YM, Levy AR, Iloeje UH, Briggs AH. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004; 38: S179-S186
3. Dybowska D, Pilarczyk M. Treatment of chronic hepatitis B Przegl Epidemiol 2004; 58 Suppl 1: 139-143
4. Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, Bujnowska A, Mozer-Lisewska I, Sluzewski W. Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res 2005;
5. Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, Tanaka S, Yoshiba M, Kohara M. Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol 1999; 37: 2899-2903
6. Vet JA, Majithia AR, Marras SA, Tyagi S, Dube S, Poiesz BJ, Kramer FR. Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc Natl Acad Sci USA 1999; 96: 6394-6399
7. Mohammadalizadeh AH, Ranjbar M, Hatami S. Risk factor for HBsAg positive state in Hamedan blood donors. Iranian J Infect Dis in press
8. Beier FJ. Risk of endangering patients by hepatitis B infected surgeons: monitoring the health of medical personnel in hospitals must be evaluated Gesundheitswesen 2000; 62: 64-70
9. Luksamijarulkul P, Maneesri P, Kittigul L. Hepatitis B sero-prevalence and risk factors among school-age children in a low socioeconomic community, Bangkok. Asia Pac J Public Health 1995; 8: 158-161
10. Hann HW, Jonsson Funk ML, Rosenberg DM, Davis R. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol 2005; 20: 433-440
11. Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl) 1999; 112: 387-391
12. Khokhar N, Gill ML, Alam AY. Treatment of chronic hepatitis B with lamivudine. J Coll Physicians Surg Pak 2005; 15: 78-80
13. Ferenci P. Treatment of chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2004; 18 Suppl: 113-120
14. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
15. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
16. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568
17. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194
18. Sokal E. Lamivudine for the treatment of chronic hepatitis B. Expert Opin Pharmacother 2002; 3: 329-339